Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera

NCT01193699 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT01193699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01193699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2010
Completion date
January 25, 2018
Enrollment
24 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera